Evidence map›Paper›PMID 39220249›Full record

ArticleNeuro-oncology advances

Frequent Alzheimer's disease neuropathological change in patients with glioblastoma.

Lisa Greutter, Yelyzaveta Miller-Michlits, Sigrid Klotz, Regina Reimann, Karl-Heinz Nenning, Stephan Platzek, Elena Krause, Barbara Kiesel, Georg Widhalm, Georg Langs and 2 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma.Journal of cellular and molecular medicine · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lisa GreutterCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0009-0005-4801-4764
Yelyzaveta Miller-MichlitsDepartment of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.
Sigrid KlotzDepartment of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-3096-2852
Regina ReimannInstitute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-6396-4195
Karl-Heinz NenningCenter for Biomedical Imaging & Neuromodulation, The Nathan S. Kline Institute for Psychiatric Research, New York City, New York, USA.ORCID https://orcid.org/0000-0002-1073-9891
Stephan PlatzekDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Elena KrauseDepartment of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.
Barbara KieselDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0003-0939-9831
Georg WidhalmDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-6014-0273
Georg LangsDepartment for Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Bernhard BaumannCenter for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-6419-1932
Adelheid WoehrerDepartment of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8435-8189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence of brain cancer and neurodegenerative diseases is increasing with a demographic shift towards aging populations. Biological parallels have been observed between glioblastoma and Alzheimer's disease (AD), which converge on accelerated brain aging. Here, we aimed to map the cooccurrence of AD neuropathological change (ADNC) in the tumor-adjacent cortex of patients with glioblastoma. Methods: Immunohistochemical screening of AD markers amyloid beta (Abeta), amyloid precursor protein (APP), and hyperphosphorylated tau (pTau) was conducted in 420 tumor samples of 205 patients. For each cortex area, we quantified ADNC, neurons, tumor cells, and microglia. Results: Fifty-two percent of patients ( Conclusions: Our findings highlight the frequent presence of ADNC in the glioblastoma vicinity, which was linked to patient age and tumor location. The cooccurrence of AD and glioblastoma seemed stochastic without clear spatial relation. ADNC did not impact patient survival in our cohort.

Indexed as

Alzheimer’s diseaseamyloid betabrain agingglioblastomahyperphosphorylated tau

Identifiers

PMID39220249
PMCPMC11362848

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.